Category Covid-19

PIER MARIA FORNASARI
2021-03-25

Individual SARS-CoV-2 neutralising antibody immunity lasts from days to decades. Patients were categorized in 5 groups: negative, rapid waining, slow waining, persistent and delayed response.

Study shows that antibody longevity varies widely from 40 days to as long as several decades and not everyone who has recovered from COVID-19 is immune from reinfection  Individuals with low levels of neutralising antibodies may still be protected if they have robust T-cell immunity Blood tests and a computer algorithm suggest annual vaccinations might

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-23

U.S. NIAID discuss results released by AstraZeneca on Covid vaccine trial: AZ might have included outdated informations.

Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-22

Aspirin use may decrease ventilation, ICU admission and death in COVID-19 patients

Researchers from the George Washington University found that aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. George Washington University researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. Final results

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-22

Astrazeneca Covid vaccine US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. No increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants.

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation Comparable efficacy result across ethnicity and age,with 80% efficacy in participants aged 65 years and over Favourable reactogenicity and overall safety profile The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-21

AstraZeneca Covid vaccine and rare thrombosis: Greifswald team suggests an autoimmune trigger in 4 of 13 German reported cases. The incidence of thrombosis in Germany is 1:123.000 doses, while in the rest of Europe 1:1.350.000.

13 cases of a venous cerebral sinus or cerebral vein thrombosis following >1,6 million doses were reported in Germany. The thrombosis occurred 4-16 days after the vaccination with the AstraZeneca COVID-19 vaccine in twelve women and one man aged 20–63 years. The patients had one at the same time thrombosis and thrombocytopenia due to autoantibodies.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-19

New special warning introduced by EMA in the summary of COVID-19 Vaccine (ChAdOx1-S [recombinant]) product characteristics

EMA has just published the new product information leaflet for Astrazeneca Covid-19 vaccine after investigations of thrombosis rare cases reported. In the section 4.4 Special warnings and precautions for use has been added the following: Thrombocytopenia and coagulation disordersA combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, hasbeen observed very rarely following

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-19

Optimal Thromboprophylaxis protocol in Patients With COVID-19

From the early days of the COVID-19 pandemic, a distinct coagulation disturbance of SARS-CoV-2 infection has been recognized. This thrombo-inflammatory phenotype, characterized by endotheliopathy, hypercoagulability, and coagulation activation, results in an increased risk of thromboembolic events. Initial observational cohort studies described high rates of venous thromboembolism (VTE) in critically ill patients with COVID-19, despite consistent use

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-19

Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2

In The Lancet, Zhenyu He and colleagues report their cross-sectional study of serological responses of morethan 9500 individuals from 3600 households in Wuhan, the early epicentre for the COVID-19 outbreak. The study was initiated shortly after lockdown in Wuhan ceased in April, 2020, with follow-up over two timepoints (June and October–December, 2020). In this cross-sectional,

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-19

CDC US COVID-19 update on new SARS-CoV-2 Variants

CDC’s national genomic surveillance program identifies new and emerging SARS-CoV-2 variants to determine implications for COVID-19 diagnostics, treatments, or vaccines authorized for use in the United States. Monitoring the spread of emerging variants in the United States relies on widespread, rapid sequencing.  To accelerate sequencing in the United States, CDC has contracted with commercial diagnostic laboratories, and,

Read More

No Comments InCovid-19